OZURDEX- dexamethasone implant
Allergan, Inc.


1.1 Retinal Vein Occlusion

OZURDEX ® (dexamethasone intravitreal implant) is indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).

1.2 Posterior Segment Uveitis

OZURDEX ® is indicated for the treatment of non-infectious uveitis affecting the posterior segment of the eye.

1.3 Diabetic Macular Edema

OZURDEX ® is indicated for the treatment of diabetic macular edema.


2.1 General Dosing Information

For ophthalmic intravitreal injection.

2.2 Administration

The intravitreal injection procedure should be carried out under controlled aseptic conditions which include the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide applied to the periocular skin, eyelid and ocular surface are recommended to be given prior to the injection.

Remove the foil pouch from the carton and examine for damage. Then, open the foil pouch over a sterile field and gently drop the applicator on a sterile tray. Carefully remove the cap from the applicator. Hold the applicator in one hand and pull the safety tab straight off the applicator. Do not twist or flex the tab . The long axis of the applicator should be held parallel to the limbus, and the sclera should be engaged at an oblique angle with the bevel of the needle up (away from the sclera) to create a shelved scleral path. The tip of the needle is advanced within the sclera for about 1 mm (parallel to the limbus), then re-directed toward the center of the eye and advanced until penetration of the sclera is completed and the vitreous cavity is entered. The needle should not be advanced past the point where the sleeve touches the conjunctiva.

Slowly depress the actuator button until an audible click is noted. Before withdrawing the applicator from the eye, make sure that the actuator button is fully depressed and has locked flush with the applicator surface. Remove the needle in the same direction as used to enter the vitreous.

Following the intravitreal injection, patients should be monitored for elevation in intraocular pressure and for endophthalmitis. Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and biomicroscopy between two and seven days following the injection. Patients should be instructed to report any symptoms suggestive of endophthalmitis without delay.

Each applicator can only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new applicator must be used, and the sterile field, syringe, gloves, drapes, and eyelid speculum should be changed before OZURDEX ® is administered to the other eye.


Intravitreal implant containing dexamethasone 0.7 mg in the N OVADUR ® solid polymer drug delivery system.


4.1 Ocular or Periocular Infections

OZURDEX ® (dexamethasone intravitreal implant) is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.

4.2 Glaucoma

OZURDEX ® is contraindicated in patients with glaucoma, who have cup to disc ratios of greater than 0.8.

4.3 Torn or Ruptured Posterior Lens Capsule

OZURDEX ® is contraindicated in patients whose posterior lens capsule is torn or ruptured because of the risk of migration into the anterior chamber. Laser posterior capsulotomy in pseudophakic patients is not a contraindication for OZURDEX ® use.

4. 4 Hypersensitivity

OZURDEX ® is contraindicated in patients with known hypersensitivity to any components of this product [see Adverse Reactions ( 6)].


5.1 Intravitreal Injection-related Effects

Intravitreal injections, including those with OZURDEX ® , have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Patients should be monitored regularly following the injection [see Patient Counseling Information ( 17)].

5.2 Steroid-related Effects

Use of corticosteroids including OZURDEX ® may produce posterior subcapsular cataracts, increased intraocular pressure, and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses [see Adverse Reactions ( 6.1)].

Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.


Figure 1: Mean IOP during the study

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Adverse reactions associated with ophthalmic steroids including OZURDEX ® include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.

Retinal Vein Occlusion and Posterior Segment Uveitis

The following information is based on the combined clinical trial results from 3 initial, randomized, 6-month, sham-controlled studies (2 for retinal vein occlusion and 1 for posterior segment uveitis):

Table 1: Adverse Reactions Reported by Greater than 2% of Patients
MedDRA Term OZURDEX ® N=497 (%)Sham N=498 (%)
Intraocular pressure increased125 (25%)10 (2%)
Conjunctival hemorrhage108 (22%)79 (16%)
Eye pain40 (8%)26 (5%)
Conjunctival hyperemia33 (7%)27 (5%)
Ocular hypertension23 (5%)3 (1%)
Cataract24 (5%)10 (2%)
Vitreous detachment12 (2%)8 (2%)
Headache19 (4%)12 (2%)

Increased IOP with OZURDEX ® peaked at approximately week 8. During the initial treatment period, 1% (3/421) of the patients who received OZURDEX ® required surgical procedures for management of elevated IOP.

Following a second injection of OZURDEX ® in cases where a second injection was indicated, the overall incidence of cataracts was higher after 1 year.

In a 2 year observational study, among patients who received >2 injections, the most frequent adverse reaction was cataract 54% (n= 96 out of 178 phakic eyes at baseline). Other frequent adverse reactions from the 283 treated eyes, regardless of lens status at baseline, were increased IOP 24% (n = 68) and vitreous hemorrhage 6.0% (n = 17).

Diabetic Macular Edema

The following information is based on the combined clinical trial results from 2 randomized, 3-year, sham-controlled studies in patients with diabetic macular edema. Discontinuation rates due to the adverse reactions listed in Table 2 were 3% in the OZURDEX ® group and 1% in the Sham group. The most common ocular (study eye) and non-ocular adverse reactions are shown in Tables 2 and 3:

Table 2: Ocular Adverse Reactions Reported by ≥ 1% of Patients and Non-ocular Adverse Reactions Reported by ≥ 5% of Patients
MedDRA Term OZURDEX ® N=324 (%)Sham N=328 (%)
Cataract1 166/2432 (68%)49/230 (21%)
Conjunctival hemorrhage73 (23%)44 (13%)
Visual acuity reduced28 (9%)13 (4%)
Conjunctivitis19 (6%)8 (2%)
Vitreous floaters16 (5%)6 (2%)
Conjunctival edema15 (5%)4 (1%)
Dry eye15 (5%)7 (2%)
Vitreous detachment14 (4%)8 (2%)
Vitreous opacities11 (3%)3 (1%)
Retinal aneurysm10 (3%)5 (2%)
Foreign body sensation7 (2%)4 (1%)
Corneal erosion7 (2%)3 (1%)
Keratitis6 (2%)3 (1%)
Anterior Chamber Inflammation6 (2%)0 (0%)
Retinal tear5 (2%)2 (1%)
Eyelid ptosis5 (2%)2 (1%)
Hypertension41 (13%)21 (6%)
Bronchitis15 (5%)8 (2%)

1 Includes cataract, cataract nuclear, cataract subcapsular, lenticular opacities in patients who were phakic at baseline. Among these patients, 61% of OZURDEX ® subjects vs. 8% of sham-controlled subjects underwent cataract surgery.

2 243 of the 324 OZURDEX ® subjects were phakic at baseline; 230 of 328 sham-controlled subjects were phakic at baseline.

Increased Intraocular Pressure

Table 3: Summary of Elevated Intraocular Pressure (IOP) Related Adverse Reactions
IOP Treatment: N (%)
OZURDEX ® N=324 Sham N=328
IOP elevation ≥10 mm Hg from Baseline at any visit91 (28%)13 (4%)
≥30 mm Hg IOP at any visit50 (15%)5 (2%)
Any IOP lowering medication136 (42%)32 (10%)
Any surgical intervention for elevated IOP * 4 (1.2%)1 (0.3%)

* OZURDEX ®: 1 surgical trabeculectomy for steroid-induced IOP increase, 1 surgical trabeculectomy for iris neovascularization,
1 laser iridotomy, 1 surgical iridectomySham: 1 laser iridotomy

The increase in mean IOP was seen with each treatment cycle, and the mean IOP generally returned to baseline between treatment cycles (at the end of the 6 month period) shown below:

Figure 1: Mean IOP during the study

Figure 1: Mean IOP during the study
(click image for full-size original)

Cataracts and Cataract Surgery

At baseline, 243 of the 324 OZURDEX ® subjects were phakic; 230 of 328 sham-controlled subjects were phakic. The incidence of cataract development in patients who had a phakic study eye was higher in the OZURDEX ® group (68%) compared with Sham (21%). The median time of cataract being reported as an adverse event was approximately 15 months in the OZURDEX ® group and 12 months in the Sham group. Among these patients, 61% of OZURDEX ® subjects vs. 8% of sham-controlled subjects underwent cataract surgery, generally between Month 18 and Month 39 (Median Month 21 for OZURDEX ® group and 20 for Sham) of the studies.

Page 1 of 3 1 2 3

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2023. All Rights Reserved.